Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

被引:49
作者
Brown, Janet E. [1 ,24 ]
Royle, Kara-Louise [2 ]
Gregory, Walter [2 ]
Ralph, Christy [5 ]
Maraveyas, Anthony [7 ]
Din, Omar [8 ]
Eisen, Timothy [9 ,10 ]
Nathan, Paul [11 ]
Powles, Tom [12 ]
Griffiths, Richard [13 ]
Jones, Robert [14 ]
Vasudev, Naveen [5 ]
Wheater, Matthew [15 ]
Hamid, Abdel [16 ]
Waddell, Tom [17 ]
McMenemin, Rhona [18 ]
Patel, Poulam [19 ]
Larkin, James [20 ]
Faust, Guy [21 ]
Martin, Adam [4 ]
Swain, Jayne [2 ]
Bestall, Janine [3 ]
McCabe, Christopher [22 ]
Meads, David [4 ]
Goh, Vicky [23 ]
Wah, Tze Min [6 ]
Brown, Julia [2 ]
Hewison, Jenny [3 ]
Selby, Peter [5 ]
Collinson, Fiona [2 ]
机构
[1] Univ Sheffield, Weston Pk Hosp, Dept Oncol & Metab, Sheffield, England
[2] University of Leeds, Leeds Inst Clin Trials Res, Leeds Canc Res UK Clin Trials Unit, Leeds, England
[3] University of Leeds, Leeds Inst Hlth Sci, Leeds, England
[4] University of Leeds, Acad Unit Hlth Econ, Leeds, England
[5] University of Leeds, Leeds Inst Med Res St Jamess, Leeds, England
[6] Univ Leeds, Leeds Inst Med Res, Dept Radiol, Leeds, England
[7] Hull York Med Sch, Fac Hlth Sci, Queens Ctr Oncol & Haematol, Kingston Upon Hull, England
[8] Sheffield Teaching Hosp, NHS Fdn Trust, Canc Ctr, Dept Clin Oncol, Sheffield, England
[9] Univ Cambridge, Dept Oncol, Cambridge, England
[10] Cambridge Univ Hosp, NHS Fdn Trust, Cambridge, England
[11] East & North Hertfordshire NHS Trust, Mt Vernon Canc Ctr, Northwood, England
[12] Queen Mary Univ, Barts Canc Inst, London, England
[13] NHS Fdn Trust, Clatterbridge Canc Ctr, Liverpool, England
[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland
[15] Univ Hosp Southampton, NHS Fdn Trust, Southampton, England
[16] Broomfield Hosp, Mid & South Essex NHS Fdn Trust, Chelmsford, England
[17] Christie NHS Fdn Trust, Manchester, England
[18] Newcastle Tyne Hosp, NHS Fdn TrustNHS Fdn Trust, Northern Ctr Canc Care, Newcastle, England
[19] Univ Nottingham, Acad Unit Translat Med Sci, Nottingham, England
[20] Royal Marsden NHS Fdn Trust, London, England
[21] Univ Hosp Leicester NHS Trust, Leicester Royal Infirm, Leicester, England
[22] Queens Univ, Ctr Publ Hlth, Belfast, North Ireland
[23] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England
[24] Univ Sheffield, Weston Pk Hosp, Dept Oncol & Metab, Sheffield S10 2SJ, England
关键词
ADVANCED COLORECTAL-CANCER; SUNITINIB RECHALLENGE; INTERFERON-ALPHA; SURVIVAL; INTERMITTENT; PAZOPANIB; CHEMOTHERAPY; OXALIPLATIN; THERAPY; EUROQOL;
D O I
10.1016/S1470-2045(22)00793-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma.Methods This open-label, non-inferiority, randomised, controlled, phase 2/3 trial was done at 60 hospital sites in the UK. Eligible patients (aged >= 18 years) had histologically confirmed clear cell renal cell carcinoma, inoperable loco -regional or metastatic disease, no previous systemic therapy for advanced disease, uni-dimensionally assessed Response Evaluation Criteria in Solid Tumours-defined measurable disease, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) at baseline to a conventional continuation strategy or drug-free interval strategy using a central computer-generated minimisation programme incorporating a random element. Stratification factors were Memorial Sloan Kettering Cancer Center prognostic group risk factor, sex, trial site, age, disease status, tyrosine kinase inhibitor, and previous nephrectomy. All patients received standard dosing schedules of oral sunitinib (50 mg per day) or oral pazopanib (800 mg per day) for 24 weeks before moving into their randomly allocated group. Patients allocated to the drug-free interval strategy group then had a treatment break until disease progression, when treatment was re-instated. Patients in the conventional continuation strategy group continued treatment. Patients, treating clinicians, and the study team were aware of treatment allocation. The co -primary endpoints were overall survival and quality-adjusted life-years (QALYs); non-inferiority was shown if the lower limit of the two-sided 95% CI for the overall survival hazard ratio (HR) was 0middot812 or higher and if the lower limit of the two-sided 95% CI of the marginal difference in mean QALYs was -0middot156 or higher. The co-primary endpoints were assessed in the intention-to-treat (ITT) population, which included all randomly assigned patients, and the per-protocol population, which excluded patients in the ITT population with major protocol violations and who did not begin their randomisation allocation as per the protocol. Non-inferiority was to be concluded if it was met for both endpoints in both analysis populations. Safety was assessed in all participants who received a tyrosine kinase inhibitor. The trial was registered with ISRCTN, 06473203, and EudraCT, 2011-001098-16.Findings Between Jan 13, 2012, and Sept 12, 2017, 2197 patients were screened for eligibility, of whom 920 were randomly assigned to the conventional continuation strategy (n=461) or the drug-free interval strategy (n=459; 668 [73%] male and 251 [27%] female; 885 [96%] White and 23 [3%] non-White). The median follow-up time was 58 months (IQR 46-73 months) in the ITT population and 58 months (46-72) in the per-protocol population. 488 patients continued on the trial after week 24. For overall survival, non-inferiority was demonstrated in the ITT population only (adjusted HR 0middot97 [95% CI 0middot83 to 1middot12] in the ITT population; 0middot94 [0middot80 to 1middot09] in the per-protocol population). Non-inferiority was demonstrated for QALYs in the ITT population (n=919) and per-protocol (n=871) population (marginal effect difference 0middot06 [95% CI -0middot11 to 0middot23] for the ITT population; 0middot04 [-0middot14 to 0middot21] for the per-protocol population). The most common grade 3 or worse adverse events were hypertension (124 [26%] of 485 patients in the conventional continuation strategy group vs 127 [29%] of 431 patients in the drug-free interval strategy group); hepatotoxicity (55 [11%] vs 48 [11%]); and fatigue (39 [8%] vs 63 [15%]). 192 (21%) of 920 participants had a serious adverse reaction. 12 treatment -related deaths were reported (three patients in the conventional continuation strategy group; nine patients in the drug -free interval strategy group) due to vascular (n=3), cardiac (n=3), hepatobiliary (n=3), gastrointestinal (n=1), or nervous system (n=1) disorders, and from infections and infestations (n=1). Interpretation Overall, non-inferiority between groups could not be concluded. However, there seemed to be no clinically meaningful reduction in life expectancy between the drug-free interval strategy and conventional continuation strategy groups and treatment breaks might be a feasible and cost-effective option with lifestyle benefits for patients during tyrosine kinase inhibitor therapy in patients with renal cell carcinoma.Funding UK National Institute for Health and Care Research. Copyright (c) 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
引用
收藏
页码:213 / 227
页数:15
相关论文
共 35 条
  • [1] Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
    Adams, Richard A.
    Meade, Angela M.
    Seymour, Matthew T.
    Wilson, Richard H.
    Madi, Ayman
    Fisher, David
    Kenny, Sarah L.
    Kay, Edward
    Hodgkinson, Elizabeth
    Pope, Malcolm
    Rogers, Penny
    Wasan, Harpreet
    Falk, Stephen
    Gollins, Simon
    Hickish, Tamas
    Bessell, Eric M.
    Propper, David
    Kennedy, M. John
    Kaplan, Richard
    Maughan, Timothy S.
    [J]. LANCET ONCOLOGY, 2011, 12 (07) : 642 - 653
  • [2] EuroQol: The current state of play
    Brooks, R
    [J]. HEALTH POLICY, 1996, 37 (01) : 53 - 72
  • [3] PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
    Buckley, Hannah L.
    Collinson, Fiona J.
    Ainsworth, Gemma
    Poad, Heather
    Flanagan, Louise
    Katona, Eszter
    Howard, Helen C.
    Murden, Geraldine
    Banks, Rosamonde E.
    Brown, Joanne
    Velikova, Galina
    Waddell, Tom
    Fife, Kate
    Nathan, Paul D.
    Larkin, James
    Powles, Thomas
    Brown, Sarah R.
    Vasudev, Naveen S.
    [J]. BMC CANCER, 2019, 19 (01)
  • [4] Cella David, 2006, J Support Oncol, V4, P191
  • [5] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE
    CELLA, DF
    TULSKY, DS
    GRAY, G
    SARAFIAN, B
    LINN, E
    BONOMI, A
    SILBERMAN, M
    YELLEN, SB
    WINICOUR, P
    BRANNON, J
    ECKBERG, K
    LLOYD, S
    PURL, S
    BLENDOWSKI, C
    GOODMAN, M
    BARNICLE, M
    STEWART, I
    MCHALE, M
    BONOMI, P
    KAPLAN, E
    TAYLOR, S
    THOMAS, CR
    HARRIS, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 570 - 579
  • [6] The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer
    Collinson, Fiona J.
    Gregory, Walter M.
    McCabe, Chris
    Howard, Helen
    Lowe, Catherine
    Potrata, DrBarbara
    Tubeuf, Sandy
    Hanlon, Pat
    McParland, Lucy
    Wah, T.
    Selby, Peter J.
    Hewison, Jenny
    Brown, Julia
    Brown, Janet
    [J]. BMC CANCER, 2012, 12
  • [7] Interpreting the results of noninferiority trials-a review
    Cuzick, Jack
    Sasieni, Peter
    [J]. BRITISH JOURNAL OF CANCER, 2022, 127 (10) : 1755 - 1759
  • [8] Electronic Medicines Compendium, SUT 12 5 MG HARD CAP
  • [9] A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials
    Faria, Rita
    Gomes, Manuel
    Epstein, David
    White, Ian R.
    [J]. PHARMACOECONOMICS, 2014, 32 (12) : 1157 - 1170
  • [10] Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma
    Kahl, Christoph
    Hilgendorf, Inken
    Freund, Mathias
    Casper, Jochen
    [J]. ONKOLOGIE, 2008, 31 (8-9): : 485 - 485